Supernus Pharmaceuticals
SUPN
294 hedge funds and large institutions have $2.15B invested in Supernus Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 102 increasing their positions, 98 reducing their positions, and 20 closing their positions.
323% more call options, than puts
Call options by funds: $994K | Put options by funds: $235K
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
15% more capital invested
Capital invested by funds: $1.86B → $2.15B (+$288M)
8% more funds holding
Funds holding: 273 → 294 (+21)
4% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 98
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.91% less ownership
Funds ownership: 108.67% → 107.76% (-0.91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$8.28M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.34M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$5.97M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.82M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$4.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.16M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$8.8M |
| 3 |
Millennium Management
New York
|
-$7.83M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$7.63M |
| 5 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
-$6.34M |
SUPN Hedge Fund Activity: Q4 2024 in Review
294 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2024, worth a combined $2.15B — up 15% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SUPN positions and 20 closed out — a net gain of 22 holders — while 102 added to existing stakes and 98 trimmed.
The largest buyer was Woodline Partners, adding an estimated $8.28M. The largest seller was Armistice Capital, cutting an estimated $9.16M.
- 294 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2024, up from 273 in Q3 2024.
- Funds reported $2.15B of Supernus Pharmaceuticals stock for Q4 2024, up 15% quarter-over-quarter.
- 42 funds opened new Supernus Pharmaceuticals positions in Q4 2024 and 20 closed out, a net change of +22 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2024 was Woodline Partners, an estimated $8.28M added.
- The largest Supernus Pharmaceuticals seller in Q4 2024 was Armistice Capital, an estimated $9.16M sold.
Based on aggregated 13F filings for Q4 2024.